跳至主要内容
临床试验/CTRI/2022/04/041843
CTRI/2022/04/041843已完成未知

A comparative study to assess the effectiveness and cardio-metabolic safety profile of Lurasidone versus Olanzapine in patients with Schizophrenia

Alok Gupta0 个研究点目标入组 114 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
114

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients giving informed consent, diagnosed with Schizophrenia as per ICD 10 diagnostic criteria and drug free for atleast 8 weeks.

排除标准

  • Known case of diabetes mellitus, dyslipidemia and cardiac illness. Systemic or neurological Disorder affecting cognition, behavior or mental status.
  • Substance dependence except nicotine and caffeine within the past month of entering the study.Long standing medical or surgical illness and patients with mental retardation or organic brain disease.

研究者

发起方
Alok Gupta

相似试验